secwatch.observer — SEC 8-K summary
======================================

Issuer:     PDS Biotechnology Corp (PDSB)
CIK:        0001472091
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001140361-24-046731
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PDS Biotech reports Q3 net loss $10.7M; modifies Phase 3 trial design to cut costs
--------------------------------------------------------------------------------

- Net loss of $10.7M ($0.29/share) vs $10.8M ($0.35/share) in Q3 2023; operating expenses declined slightly.
- Cash and equivalents $49.8M as of Sept 30, 2024; cash runway supports VERSATILE-003 launch.
- Phase 3 VERSATILE-003 trial design modified: ~350 patients, 2:1 randomization, overall survival primary endpoint.
- Amended IND submitted Nov 2024; FDA clearance expected by mid-Dec; site activation targeted Q1 2025.
- R&D expenses $6.8M (+$0.4M YoY) on higher manufacturing; G&A $3.4M (-$0.7M YoY) on lower personnel costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124046731/0001140361-24-046731-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472091/000114036124046731/ef20038649_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-046731

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer